Two Molecules Offer Insight for Estrogen Driven Breast Cancer Treatment

In Florida, California, and Illinois, researchers from several universities have found that two molecules in the immune system are crucial to drug resistance in breast cancers. Most breast cancer tumors are compelled by estrogen and drug treatments often include estrogen suppression, but unfortunately about half of patients don’t respond to those treatments. However, now that researchers know that two molecules, called interleukin 1 beta and tumor necrosis factor alpha, are responsible for the drug resistance in patients, it offers researchers key insights. Researchers hope to use the information and genomic, cellular and biochemical approaches to develop new treatments to block the resistance process for breast cancer patients.